MARKETS / NASDAQ / LUNG
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Pulmonx Corporation LUNG

8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$90.5M
▲ 8.0% vs FY2024
EPS · FY25
$-1.33
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-77.2%
Net margin · FY25
-59.7%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 90.5M
Revenue, FY2025 · full 8-year series below
Revenue Net income
0.0250.050.0750.10.1-0.12018202120242025
0.0250.050.0750.10.1-0.12018202120242025

The company lost 60 cents on every revenue dollar this year.

Per share
USD -1.33
Diluted EPS, FY2025
EPS
0.40.81.2-1.332018202120242025
0.40.81.2-1.332018202120242025

The company pays no cash dividend.

Profitability
-77.2%
Return on equity, FY2025
ROE
0.250.50.751-77.2%2018202120242025
0.250.50.751-77.2%2018202120242025
Operating margin-59.3%
Net margin-59.7%
Return on assets-37.0%

Each USD of equity lost 77 cents this year.

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+22.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+19.0%
+22.6%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.04B
Shares outstanding, FY2025
0.000.042018202120242025
0.000.042018202120242025
Change, 5 years+16.8%
Change, 10 years

The share count grew 17% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 129.3M
total assets, end of FY2025
Total assetsUSD 129.3M
EquityUSD 54.1M
CashUSD 69.8M
Gross debtUSD 37.1M
Net debtUSD -32.7M
Current ratio5.07×

The company holds more cash than debt.

History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.33
−1.44
−1.60
−1.59
−1.35
−3.16
−11.66
−11.03
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−77.2
−55.3
−44.7
−33.9
−23.2
−166.3
·
·
Shares out B
0.04
0.04
0.04
0.04
0.04
0.04
0.00
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
30 of 30
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed